Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Monday. The brokerage set a “hold” rating on the medical research company’s stock.

A number of other research firms have also recently issued reports on CTSO. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a research report on Monday, July 29th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th.

Cytosorbents Stock Down 5.8 %

Shares of NASDAQ CTSO opened at $0.90 on Monday. The company has a quick ratio of 1.71, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The firm has a market cap of $48.94 million, a PE ratio of -2.49 and a beta of 0.56. The company’s fifty day simple moving average is $1.12 and its 200 day simple moving average is $1.01. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $2.15.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CTSO. CM Management LLC increased its position in shares of Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares in the last quarter. Sargent Investment Group LLC lifted its position in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. acquired a new position in Cytosorbents during the 3rd quarter valued at about $51,000. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Avenir Corp raised its stake in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after purchasing an additional 121,294 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.